» Articles » PMID: 21285253

Forkhead Transcription Factor Foxq1 Promotes Epithelial-mesenchymal Transition and Breast Cancer Metastasis

Overview
Journal Cancer Res
Specialty Oncology
Date 2011 Feb 3
PMID 21285253
Citations 103
Authors
Affiliations
Soon will be listed here.
Abstract

Epithelial-mesenchymal transition (EMT) promotes cancer invasion and metastasis, but the integrative mechanisms that coordinate these processes are incompletely understood. In this study, we used a cross-species expression profiling strategy in metastatic cell lines of human and mouse origin to identify 22 up-regulated and 12 down-regulated genes that are part of an essential genetic program in metastasis. In particular, we identified a novel function in metastasis that was not previously known for the transcription factor Forkhead Box Q1 (Foxq1). Ectopic expression of Foxq1 increased cell migration and invasion in vitro, enhanced the lung metastatic capabilities of mammary epithelial cells in vivo, and triggered a marked EMT. In contrast, Foxq1 knockdown elicited converse effects on these phenotypes in vitro and in vivo. Neither ectopic expression nor knockdown of Foxq1 significantly affected cell proliferation or colony formation in vitro. Notably, Foxq1 repressed expression of the core EMT regulator E-cadherin by binding to the E-box in its promoter region. Further mechanistic investigation revealed that Foxq1 expression is regulated by TGF-β1, and that Foxq1 knockdown blocked TGF-β1-induced EMT at both morphological and molecular levels. Our findings highlight the feasibility of cross-species expression profiling as a strategy to identify metastasis-related genes, and they reveal that EMT induction is a likely mechanism underlying a novel metastasis-promoting function of Foxq1 defined here in breast cancer.

Citing Articles

The transcription factor FOXQ1 in cancer.

Koch S Cancer Metastasis Rev. 2025; 44(1):22.

PMID: 39777582 PMC: 11711781. DOI: 10.1007/s10555-025-10240-y.


YWHAB is regulated by IRX5 and inhibits the migration and invasion of breast cancer cells.

Geng X, Yuan J, Xu W, Zou D, Sun Y, Li J Oncol Lett. 2024; 28(4):469.

PMID: 39119237 PMC: 11306988. DOI: 10.3892/ol.2024.14602.


Phosphorylated FOXQ1, a novel substrate of JNK1, inhibits sorafenib-induced ferroptosis by activating ETHE1 in hepatocellular carcinoma.

Liu Y, Shao K, Yang W, Shen Q, Lu M, Shao Z Cell Death Dis. 2024; 15(6):395.

PMID: 38839744 PMC: 11153576. DOI: 10.1038/s41419-024-06789-1.


ELF3 plays an important role in defining TRAIL sensitivity in breast cancer by modulating the expression of decoy receptor 2 (DCR2).

Ghosal N, Tapadar P, Biswas D, Pal R Mol Biol Rep. 2024; 51(1):671.

PMID: 38787503 DOI: 10.1007/s11033-024-09615-1.


Transcriptome analysis provides insights into high fat diet-induced kidney injury and moderate intensity continuous training-mediated protective effects.

Hong W, Luan Y, Ma Y, Zhang B, Xiong Y Heliyon. 2024; 10(5):e27157.

PMID: 38444510 PMC: 10912694. DOI: 10.1016/j.heliyon.2024.e27157.


References
1.
Rahimi R, Leof E . TGF-beta signaling: a tale of two responses. J Cell Biochem. 2007; 102(3):593-608. DOI: 10.1002/jcb.21501. View

2.
Mani S, Yang J, Brooks M, Schwaninger G, Zhou A, Miura N . Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers. Proc Natl Acad Sci U S A. 2007; 104(24):10069-74. PMC: 1891217. DOI: 10.1073/pnas.0703900104. View

3.
Dontu G, Liu S, Wicha M . Stem cells in mammary development and carcinogenesis: implications for prevention and treatment. Stem Cell Rev. 2006; 1(3):207-13. DOI: 10.1385/SCR:1:3:207. View

4.
Chen D, Zhao M, Mundy G . Bone morphogenetic proteins. Growth Factors. 2004; 22(4):233-41. DOI: 10.1080/08977190412331279890. View

5.
Marhaba R, Zoller M . CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol. 2004; 35(3):211-31. DOI: 10.1023/b:hijo.0000032354.94213.69. View